Revance Therapeutics, Inc. Provides RHA® Collection Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021
For the full year, the company expects unaudited RHA® Collection revenue of between $70.0 million and $71.0 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.405 USD | +2.78% | -15.51% | -72.41% |
1st Jan change | Capi. | |
---|---|---|
-72.41% | 244M | |
+2.97% | 94.74B | |
-3.68% | 37.28B | |
-11.66% | 32.68B | |
+74.21% | 27.72B | |
-13.92% | 16.19B | |
-2.34% | 13.88B | |
-12.21% | 11.58B | |
+188.83% | 10.92B | |
-53.94% | 9.54B |